OPRX250117P35000
- 0.00
- 0.000.00%
OptimizeRx Newsroom
OptimizeRx (OPRX) Was Downgraded to a Hold Rating at Stifel Nicolaus
OptimizeRx Analyst Ratings
RBC Capital Downgrades OptimizeRx(OPRX.US) to Hold Rating, Cuts Target Price to $6
RBC Downgrades OptimizeRx to Sector Perform From Outperform, Cuts Price Target to $6 From $7
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $11
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $13
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial Outlook
Stephens Maintains OptimizeRx(OPRX.US) With Hold Rating, Cuts Target Price to $5.5
OptimizeRx Analyst Ratings
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $11
Analysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)
OptimizeRx Price Target Cut to $5.00/Share From $11.00 by Barclays
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
Roth MKM Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $16
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Ontrak (OTRK) and Ayr Wellness (OtherAYRWF)
OptimizeRx Is Maintained at Market Outperform by JMP Securities
OptimizeRx Analyst Ratings